Nifedipine Retard as Monotherapy for Essential Hypertension: A Randomized Controlled Cross-over Study

  • K. S. Woo
  • C. O. Pun
  • J. Vallance-Owen
Conference paper

Abstract

Over the past couple of decades diuretics, methyldopa, and β-blockers have been the common drugs used as first-line regimen for treating hypertension [1–3]. Some large-scale long-term studies, however, have unmasked certain side effects of the diuretics and β-blockers, and they were seen not to be well tolerated in certain patients [4–9]. These findings have stimulated interest in the search for alternative regimens. Calcium antagonists have been found to be safe and effective in treating hypertensive crisis as well as resistant hypertension, although experience is still limited regarding its application as a firststep monotherapy regimen in hypertension [10–11]. With the availability of a long-acting preparation of nifedipine that is more convenient for users, the application of nifedipine as a first-line drug for treating mild to moderate hypertension may prove desirable and appealing [12–13].

Keywords

Placebo Cholesterol Urea Creatinine Titration 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Institute of Health (1973) Executive summary of the task force reports to the Hypertension Information and Education Advisory Committee. In: National high blood pressure education program, Bethesda, National Institute of Health, Washington, pp 1–20Google Scholar
  2. 2.
    Grimm RH, Luephker RV, Taylor H, Blackburn H (1982) Long term effects of a blood pressure survey on patient treatment in a community. Circulation 65: 946–950PubMedCrossRefGoogle Scholar
  3. 3.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents (1982) Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short term titration with emphasis on racial differences in response. JAMA 248: 1966–2003Google Scholar
  4. 4.
    Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248: 1465–1477Google Scholar
  5. 5.
    Medical Research Council Working Party (1981) Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet ii: 539–544Google Scholar
  6. 6.
    McCarron DA (1984) Diuretic therapy for mild hypertension: the real cost of treatment. Am J Cardiol 53: 9A - 11APubMedCrossRefGoogle Scholar
  7. 7.
    Kaplan NM (1984) Therapy of mild hypertension: an overview. Am J Cardiol 53: 2A–8APubMedCrossRefGoogle Scholar
  8. 8.
    Opie LH (1984) Drugs and the heart four years on. Lancet i: 496–500Google Scholar
  9. 9.
    Koncaid-Smith P (1984) Beta-adrenergic receptor blocking drugs in hypertension. Special reference to their use as initial therapy. Am J Cardiol 53: 12A–15ACrossRefGoogle Scholar
  10. 10.
    Bayly S, Dobbs RJ, Robinson BF (1982) Nifedipine in the treatment of hypertension: Report of a double-blind controlled trial. Clin Pharmacol 14: 509–512Google Scholar
  11. 11.
    Frishman W, Charlap S, Kimmel B et al. (1986) Twice-daily administration of oral Verapamil in the treatment of essential hypertension. Arch Intern Med 46: 561–565CrossRefGoogle Scholar
  12. 12.
    Hornung Rs, Gould Ba, Jones RI, Sonecha TN, Raftery EB (1983) Nifedipine tablets for systemic hypertension: A study using continuous ambulatory intraarterial recording. Am J Cardiol 51: 1323–1327Google Scholar
  13. 13.
    Banzet O, Colin JN, Thibonnier M, Singlas E, Alexandre JM, Corvol P (1983) Acuteantihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine. Europ J Clin Pharmacol 24: 145–150CrossRefGoogle Scholar
  14. 14.
    Swinscow TVD (1976) The chi-square tests. Br Med J 2: 291–292PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • K. S. Woo
    • 1
  • C. O. Pun
    • 1
  • J. Vallance-Owen
    • 1
  1. 1.Department of MedicineThe Chinese University of Hong Kong, Prince of Wales HospitalShatin, NTHong Kong

Personalised recommendations